Search - tctmd.com

Displaying 1 - 20 of 93

Sort: Relevancy | Date

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Platelet Reactivity High in Most Patients Who Develop Stent Thrombosis

L.A. McKeown

December 20, 2017

News Daily News

Coronary CTA in the ED for Chest Pain Ups Statins, Aspirin on Discharge in Those at Highest Risk

Yael L. Maxwell

December 12, 2017

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

Todd Neale

November 16, 2017

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

Presentation AHA 2017

Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial

Presenter: Andre Lamy

November 15, 2017

News Conference News AHA 2017

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

Shelley Wood

November 14, 2017

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

News Conference News AHA 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

Shelley Wood

November 09, 2017

News Conference News TCT 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Todd Neale

November 01, 2017

Presentation TCT 2017

TCT 101: Safety of Double Antiplatelet Therapy as an Alternative to Warfarin Plus Aspirin After Left Atrial Appendage Device Closure - Short-Term Results of WATCHMAN-DAPT Multi-Center Registry

Presenter: Brij Maini, Petr Neuzil, Grzegorz Smolka, MD

October 31, 2017

Presentation TCT 2017

TCT 76: Impact of Post-Discharge Dual Antiplatelet Therapy vs Aspirin Alone After CABG in Patients With Left Main Disease: Results from the EXCEL Trial

Presenter: Adrian P. Banning, John D. Puskas, Christopher Kelly, MD

October 31, 2017

Presentation TCT 2017

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington

October 30, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

Shelley Wood

October 29, 2017

News Daily News

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

Yael L. Maxwell

October 23, 2017

News Daily News

CVD Risk for Women Rises After Gestational Diabetes

Yael L. Maxwell

October 16, 2017

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

Advertisement

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Platelet Reactivity High in Most Patients Who Develop Stent Thrombosis

Coronary CTA in the ED for Chest Pain Ups Statins, Aspirin on Discharge in Those at Highest Risk

RE-DUAL PCI Findings Consistent Across Key Subgroups

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

TCT 101: Safety of Double Antiplatelet Therapy as an Alternative to Warfarin Plus Aspirin After Left Atrial Appendage Device Closure - Short-Term Results of WATCHMAN-DAPT Multi-Center Registry

TCT 76: Impact of Post-Discharge Dual Antiplatelet Therapy vs Aspirin Alone After CABG in Patients With Left Main Disease: Results from the EXCEL Trial

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

TCTMD’s Top 10 Most Popular Stories for October 2017

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

CVD Risk for Women Rises After Gestational Diabetes

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content